Stifel reiterates Amylyx stock rating on avexitide confidence
Stifel maintained a Buy rating and $45 price target for Amylyx (AMLX), citing confidence in avexitide's Phase 3 data and commercial potential. The stock is up 141% YTD. Other analysts raised price targets post-trial results, with a consensus Strong Buy rating. Avexitide showed a 55% reduction vs. placebo in the LUCIDITY trial.
How this was made
The 30-second read
Why it matters
Analyst upgrades reflect confidence in commercial opportunity, potentially driving AMLX shares higher in the short term.
Market read
Positive trial data and analyst upgrades make AMLX a near‑term trade candidate.
What to watch
Potential competition from other post‑bariatric hypoglycemia therapies and reimbursement uncertainty.
Background
Amylyx Pharmaceuticals (NASDAQ:AMLX) is a biotech developing avexitide for post‑bariatric hypoglycemia. The LUCIDITY Phase 3 trial recently reported a 55% reduction versus placebo.
Ticker impact
Stifel reiterated a Buy rating and $45 price target for Amylyx Pharmaceuticals, citing strong Phase 3 avexitide data and upcoming NDA filing.
likely upside as market prices in higher success probability for avexitide.
Multiple analysts raised price targets to $55‑$57 after the LUCIDITY trial showed a 55% reduction versus placebo, indicating strong commercial potential.
Market effects
Positive data may lift other rare‑disease biotech stocks.
US biotech sector gains from trial success.
Limited to investors focused on rare‑endocrinology therapeutics.
Counterpoint
If the NDA is delayed or regulatory hurdles arise, the upside could be muted.
Key entities
- AnalystStifel
Reiterated Buy rating and $45 price target.
- AnalystGuggenheim
Raised price target to $57.
- AnalystH.C. Wainwright
Raised price target to $55.
